CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 84 enrolled
Drug / intervention
Gemcitabine +3 moredrug
Likely dose
Avastin 5 mg/kg IV; Gemcitabine 900 mg/m² IV weekly for 6 weeks every 8 weeks (A+FFG arm) OR Oxaliplatin 85 mg/m² IV on day 1 of 14-day cycle with 5FU/folinic acid (A+FOLFOX4 arm)AI-extracted
Key inclusion· 4
  • Histological or cytological diagnosis of colon or rectum cancer with Stage III unresectable or Stage IV disease
  • Urine protein <1+ on dipstick, or if ≥1+, then 24-hour urine protein <500 mg
  • No prior chemotherapy for metastatic disease; one prior adjuvant regimen allowed if progression >6 months since last treatment (Capecitabine, CPT-11, 5FU/LV, or radiation allowed, but not oxaliplatin)
  • Prior radiation therapy allowed; must have recovered from acute toxic effects. Palliative radiation to non-measurable sites acceptable if >4 weeks prior or other non-irradiated measurable disease present
Key exclusion· 6
  • Histology other than adenocarcinoma
  • Tumors with free perforation (free air or fluid in abdomen); walled-off perforation allowed
  • Active gastroduodenal ulcer on endoscopy
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days; core biopsy or minor procedure within 7 days

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00192075
NCT00192075Phase 2Completed

A Multicenter, Randomized Phase II Trial of Avastin Plus Gemcitabine Plus 5FU/Folinic Acid (A + FFG) vs. Avastin Plus Oxaliplatin Plus 5FU/Folinic Acid (A + FOLFOX 4) as Therapy for Patients With Metastatic Colorectal Cancer

Eli Lilly and Company·interventional·Posted Sep 19, 2005·Updated Feb 7, 2011

In Brief

A Phase 2 clinical trial evaluating Gemcitabine, avastin, and 2 other interventions for Colorectal Cancer. Completed, enrolled 84 participants across 15 sites.

Detailed Summary

The purpose of the study is to describe the tumor response rates for the two regimens being studied, and to determine how long patients live after receiving the treatment, how long patients are without return of their disease after they receive treatment, and how long the response they get from the treatment lasts. The amount and type of side effects/toxicities of each regimen will also be evaluated. The regimen including Oxaliplatin + 5FU/Folinic Acid is a current standard of care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 19, 2005
Enrollment StartJun 1, 2003
Study CompletionNov 1, 2007
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

Gemcitabinedrug

900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.

avastindrug

5 milligrams per kilogram (mg/kg)

5FU/folinic aciddrug

Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG). Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4). 5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).

oxaliplatindrug

85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.